Eli Lilly on Thursday raised its net profit forecast for 2012 to reflect income from the early payment of financial obligations from former partner Amylin Pharmaceuticals, which has been acquired by Bristol-Myers Squibb.
It said it now expects net earnings per share to range between $3.72 and $3.82. Its forecast for earnings excluding one-time items remains unchanged.
Ineos CEO Ineos calls on European politicians to save the chemical industry.
Merck to acquire the chromatography business of JSR Life Sciences, a leading provider of CDMO services, preclinical and translational clinical research, and bioprocessing solutions.
Carbon black manufacturer Orion Engineered Carbons plans to rationalize production lines in North and South America and EMEA.
Novo Nordisk announced a global workforce reduction of approximately 9,000 positions to streamline operations and reinvest DKK 8 billion (€1 billion) in growth opportunities for diabetes and obesity treatments.
